Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.

Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.

Abstract: The present disclosure generally relates to nucleic acid molecules for use in regulating gene expression. Disclosed herein include nucleic acid molecules containing one or more structural elements of the viral capsid enhancer operably linked to a coding sequence of a gene of interest. In some embodiments, the viral capsid enhancer comprises a Downstream Loop (DLP) from a viral capsid protein, or a variant of the DLP.

Abstract: The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.

Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.

Abstract: The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.

Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.

Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.

Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.

Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating cancer.

Abstract: A method for controlling operation of a lighting system is provided. The method includes operating the lighting system in a first mode during a time period to provide a first light output. The first output can be a blend of HINS light and non-HINS light. The method includes determining a dosage amount of HINS light provided during the time period. Furthermore, the method includes operating the lighting system in a second mode to provide a second lighting output. The second light output can be HINS light or a blend of HINS light and non-HINS light. Furthermore, spectral energy associated with HINS light in the second light output is greater than spectral energy associated with the HINS light in the first light output.

Abstract: Multi-function lighting fixtures are provided. In one example implementation, a lighting fixture may include an optical housing extending lengthwise between a first end and a second end. The optical housing may include a plurality of light sources disposed within an interior of the optical housing and a plurality of optical elements disposed along an exterior of the optical housing. The optical housing may also a plurality of sections defined within the interior of the optical housing. Each of the optical sections may be associated with a separate light source of the plurality of light sources and a separate optical element of the plurality of optical elements.

Abstract: Nucleic acid molecules encoding hepatitis B virus (HBV) surface antigens, HBV core antigens, and HBV polymerase antigens, and related combinations, are described. Also described are vectors, such as DNA plasmids or viral vectors, and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the pharmaceutical compositions of the invention are also described.

Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.

Abstract: A wall-wash lighting fixture is provided. The wall-wash lighting fixture includes a solid-state light source having a light emitting surface configured to emit light. The light emitting surface is a long dimension of the light emitting surface. The wall-wash lighting fixture further includes a frustoconical structure. The solid-state light source is positioned to emit light into the frustoconical structure. The wall-wash lighting fixture includes a reflector coupled to the frustoconical structure such that light exiting frustoconical structure is reflected at a non-parallel angle relative to a vertical axis associated with the wall-wash lighting fixture. The reflector defines an opening.

Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.

Abstract: Multi-function lighting fixtures are provided. In one example implementation, a lighting fixture may include an optical housing extending lengthwise between a first end and a second end. The optical housing may include a plurality of light sources disposed within an interior of the optical housing and a plurality of optical elements disposed along an exterior of the optical housing. The optical housing may also a plurality of sections defined within the interior of the optical housing. Each of the optical sections may be associated with a separate light source of the plurality of light sources and a separate optical element of the plurality of optical elements.

Abstract: Multi-function lighting fixtures are provided. In one example implementation, a lighting fixture may include an optical housing extending lengthwise between a first end and a second end. The optical housing may include a plurality of light sources disposed within an interior of the optical housing and a plurality of optical elements disposed along an exterior of the optical housing. The optical housing may also a plurality of compartments defined within the interior of the optical housing. Each of the optical compartments may be associated with a separate light source of the plurality of light sources and a separate optical element of the plurality of optical elements.

Abstract: A wall-wash lighting fixture is provided. The wall-wash lighting fixture includes a solid-state light source having a light emitting surface configured to emit light. The light emitting surface is a long dimension of the light emitting surface. The wall-wash lighting fixture further includes a frustoconical structure. The solid-state light source is positioned to emit light into the frustoconical structure. The wall-wash lighting fixture includes a reflector coupled to the frustoconical structure such that light exiting frustoconical structure is reflected at a non-parallel angle relative to a vertical axis associated with the wall-wash lighting fixture. The reflector defines an opening.

Abstract: A respiratory interface device, a cushion body and a cushion support assembly is provided. The respiratory interface device cushion body includes a nose bridge engagement portion structured to engage a user's nose bridge, the cushion nose bridge engagement portion movable between an un-deformed first configuration and a deformed second configuration. The cushion support assembly includes a faceplate and a pressure distributing assembly. A faceplate perimeter nose bridge portion defines a recessed tapered contour. A pressure distributing assembly includes a number of pressure distributing members. A pressure distributing member is disposed at the faceplate perimeter nose bridge portion and is structured to move between a first position, wherein the pressure distributing member maintains the cushion in the first cushion configuration, and a second position wherein the pressure distributing member maintains the cushion in the second cushion configuration.